|Bid||12.93 x 800|
|Ask||33.00 x 800|
|Day's Range||31.42 - 32.49|
|52 Week Range||17.86 - 34.28|
|Beta (5Y Monthly)||0.45|
|PE Ratio (TTM)||40.40|
|Earnings Date||Nov 01, 2023 - Nov 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.42|
Subscribe to Yahoo Finance Plus to view Fair Value for CORT
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.